Maxim Group Boosts Soligenix Inc. (SNGX) Price Target to $5.00

Soligenix Inc. (NASDAQ:SNGX) had its target price raised by equities researchers at Maxim Group from $4.00 to $5.00 in a research note issued on Monday, reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target would indicate a potential upside of 118.26% from the company’s previous close.

Separately, HC Wainwright initiated coverage on Soligenix in a research note on Monday, July 17th. They issued a “buy” rating for the company.

Shares of Soligenix (NASDAQ SNGX) opened at 2.2908 on Monday. Soligenix has a one year low of $2.26 and a one year high of $14.40. The stock’s 50 day moving average price is $2.26 and its 200-day moving average price is $2.45. The stock’s market cap is $12.99 million.

Soligenix (NASDAQ:SNGX) last announced its quarterly earnings data on Friday, August 11th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.09. The business had revenue of $1 million during the quarter, compared to analysts’ expectations of $1.43 million. Soligenix had a negative return on equity of 120.35% and a negative net margin of 86.15%. On average, equities analysts predict that Soligenix will post ($1.40) earnings per share for the current fiscal year.

WARNING: “Maxim Group Boosts Soligenix Inc. (SNGX) Price Target to $5.00” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at

About Soligenix

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with's FREE daily email newsletter.

Leave a Reply